Valsartan improves β-cell function and insulin sensitivity in subjects with impaired glucose metabolism: A randomized controlled trial

Diabetes Care

Volumn 34, Issue 4, 2011, Pages 845-851

  Van Der Zijl, Nynke J ^a   Moors, Chantalle C M ^b   Goossens, Gijs H ^b   Hermans, Marc M H ^b   Blaak, Ellen E ^b   Diamant, Michaela ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; INSULIN; PLACEBO; VALSARTAN;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; GENDER; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN RECEPTOR ANTAGONISTS; BLOOD GLUCOSE; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; TETRAZOLES; VALINE;

EID: 79956188610     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-2224     Document Type: Article

References (25)

1. Lastra-Lastra G, Sowers JR, Restrepo-Erazo K, Manrique-Acevedo C, Lastra-González G. Role of aldosterone and angiotensin II in insulin resistance: an update. Clin Endocrinol (Oxf) 2009;71:1-6
2. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 1996;93:12490-12495 (Pubitemid 26367171)
3. Shiuchi T, Iwai M, Li HS, et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004;43:1003-1010 (Pubitemid 38579905)
4. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998;41:127-133 (Pubitemid 28088387)
5. Julius S, Kjeldsen SE, Weber M, et al.; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031
6. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005;23:463-473 (Pubitemid 40684700)
7. McMurray JJ, Holman RR, Haffner SM, et al.; NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-1490
8. Fogari R, Preti P, Zoppi A, et al. Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. Intern Med 2008;47:1851-1857
9. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002;51:1699-1707 (Pubitemid 34564280)
10. Lupi R, Del Guerra S, Bugliani M, et al. The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. Eur J Endocrinol 2006;154:355-361
11. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. Diabetes 2004;53:989-997 (Pubitemid 38436611)
12. Bokhari S, Israelian Z, Schmidt J, Brinton E, Meyer C. Effects of angiotensin II type 1 receptor blockade on b-cell function in humans. Diabetes Care 2007;30:181 (Pubitemid 46052522)
13. Suzuki K, Nakagawa O, Aizawa Y. Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance. Clin Exp Hypertens 2008;30:309-314 (Pubitemid 352009289)
14. Walker M, Mari A, Jayapaul MK, Bennett SM, Ferrannini E. Impaired beta cell glucose sensitivity and whole-body insulin sensitivity as predictors of hyperglycaemia in non-diabetic subjects. Diabetologia 2005;48:2470-2476 (Pubitemid 41738209)
15. Bosch J, Yusuf S, Gerstein HC, et al.; DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-1562 (Pubitemid 44550032)
16. Leung PS, Carlsson PO. Pancreatic islet renin angiotensin system: its novel roles in islet function and in diabetes mellitus. Pancreas 2005;30:293-298 (Pubitemid 40586804)
17. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and betacell function. Best Pract Res Clin Endocrinol Metab 2003;17:305-322
18. DeFronzo RA, Tobin JD, Andres R. Glucoseclamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223 (Pubitemid 9249478)
19. Goossens GH, Blaak EE, Saris WH, van Baak MA. Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects. J Clin Endocrinol Metab 2004;89:2690-2696 (Pubitemid 38766351)
20. Kodama J, Katayama S, Tanaka K, Itabashi A, Kawazu S, Ishii J. Effect of captopril on glucose concentration. Possible role of augmented postprandial forearm blood flow. Diabetes Care 1990;13:1109-1111
21. Furuhashi M, Ura N, Takizawa H, et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004;22:1977-1982 (Pubitemid 39336681)
22. Hsueh W, Davidai G, Henry R, Mudaliar S. Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension. J Clin Hypertens (Greenwich) 2010;12:746-752
23. Sowers JR, Raij L, Jialal I, et al. Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives. J Hypertens 2010;28:1761-1769
24. Bakris G, Molitch M, Hewkin A, et al.; STAR Investigators. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006;29:2592-2597
25. Meyer C, Pimenta W, Woerle HJ, et al. Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 2006;29:1909-1914 (Pubitemid 44156651)